TRVI insider buying and SEC filings, explained
Trevi Therapeutics, Inc. · CIK 1563880
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$596K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 15, 2026 | Planned (10b5-1) | Michael Thomas Heffernan (Director) sold 39,473 shares at about $15.09 ($596K), marked as a 10b5-1 plan trade. Holdings down 86% to 6,351 shares. | SEC filing Filed Sep 17, 2026 |
21 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TRVI in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.